IJIMM, Volume 3, Issue 1, 2025 ISSN: 2995-5319
http://medicaljournals.eu/index.php/IJIMM/issue/view/3
INTERNATIONAL JOURNAL OF INTEGRATIVE AND MODERN MEDICINE

Hepatic Encephalopathy: A Key Complication of Portal Hypertension

Tolibov Farrux Farhodivich
Asia International University, Bukhara, Uzbekistan

Annotation: Liver encephalopathy is defined as a potentially reversible disorder of brain function occurring in patients with portal hypertension on the background of chronic liver disease and characterised by decreased intellectual functions, personality disorders and EEG changes. It is based on decreased hepatic clearance of substances formed in the intestine as a consequence of hepatic cellular insufficiency and due to shunting, as well as impaired amino acid metabolism.

Keywords: Liver encephalopathy, portal hypertension, chronic liver disease, hypoglycaemia, Complications, cirrhosis, mucosa, coma, atrophy,pain,disorders, clinical forms, shunt, symptom, manifestation, perforation,penetration, drug overdose, the portal vein system.

Introduction.

Hepatic encephalopathy (HE) is a debilitating neuropsychiatric disorder resulting from severe liver dysfunction, commonly associated with advanced chronic liver diseases, including cirrhosis. The syndrome manifests as a spectrum of neurological and cognitive abnormalities, ranging from subtle mood and behavioral changes to profound confusion, disorientation, and even coma. HE arises primarily due to the liver's inability to detoxify neurotoxic substances, particularly ammonia, which accumulates in the bloodstream and disrupts brain function.

The underlying pathophysiology of HE is multifactorial, with hyperammonemia being the central culprit. However, its development is also influenced by systemic inflammation, oxidative stress, alterations in gut microbiota, and metabolic dysfunctions. Portal hypertension, a hallmark of cirrhosis, contributes significantly to the onset of HE by promoting the formation of portosystemic shunts. These vascular pathways allow toxins, including ammonia and endotoxins produced in the gut, to bypass the liver and enter systemic circulation directly.

Beyond hyperammonemia, systemic inflammation and gut-derived endotoxins play synergistic roles in the neuroinflammatory response observed in HE. Chronic liver dysfunction is associated with increased intestinal permeability, allowing bacterial products to enter the bloodstream. This exacerbates inflammation and contributes to astrocyte dysfunction in the brain, further impairing cognitive and motor functions.

Hepatic encephalopathy imposes a significant burden on affected individuals, their families, and healthcare systems globally. The condition reduces the quality of life, impairs daily functioning, and increases the risk of mortality. Subclinical or minimal HE, often underdiagnosed, can manifest as subtle cognitive deficits that impair attention, memory, and decision-making, thereby affecting patients' ability to work and perform complex tasks. More severe forms of HE are associated with recurrent hospitalizations and higher healthcare costs.

Diagnosing HE remains a challenge due to its variable presentation and the lack of standardized diagnostic criteria for its subclinical forms. Psychometric testing, neuroimaging, and serum ammonia levels are commonly employed diagnostic tools, but they often fail to provide definitive conclusions in early stages. Emerging diagnostic approaches, such as the integration of psychometric hepatic encephalopathy score (PHES) with advanced imaging and gut microbiota profiling, may provide more precise and earlier detection in the future.

The management of HE focuses on reducing ammonia production and improving detoxification mechanisms. The mainstays of treatment include lactulose, a non-absorbable disaccharide that reduces

intestinal ammonia absorption, and rifaximin, a gut-selective antibiotic that modulates gut microbiota and reduces ammonia-producing bacteria. Nutritional support, particularly the use of branched-chain amino acids, plays an essential role in correcting protein-energy malnutrition commonly observed in patients with HE.

Non-pharmacological approaches, including dietary management, regular monitoring, and interventions targeting portal hypertension, are critical for comprehensive care. Advances in therapeutic strategies, such as fecal microbiota transplantation (FMT) and the use of probiotics, are currently under investigation for their potential to modulate the gut-liver-brain axis.

Despite advancements, significant gaps remain in understanding the pathogenesis and optimal management of HE. A multidisciplinary approach that integrates hepatology, neurology, and nutrition is essential to address these challenges. Future research should focus on identifying biomarkers for early detection, improving therapeutic interventions, and exploring the role of emerging technologies such as artificial intelligence in monitoring and predicting disease progression.

This study aims to provide a comprehensive review of HE, emphasizing its complex pathophysiology, the relationship with portal hypertension, and the potential for innovative diagnostic and therapeutic strategies. By addressing these aspects, the research contributes to ongoing efforts to improve patient outcomes and reduce the global burden of hepatic encephalopathy.

Materials and Methods

This study is a literature review that analyzes the diagnostic and therapeutic approaches for hepatic encephalopathy (HE). Data was collected from peer-reviewed articles, clinical trials, and reviews published between 2010 and 2024 from sources such as PubMed, Scopus, and Web of Science. Key search terms included "hepatic encephalopathy," "liver dysfunction," and "ammonia neurotoxicity."

Inclusion criteria consisted of studies focused on the pathophysiology, diagnosis, and management of HE, while excluding animal model studies and those with insufficient data. Psychometric hepatic encephalopathy score (PHES) data from clinical trials were analyzed for cognitive impairment assessment. Where applicable, meta-analysis was used for statistical evaluation of therapeutic interventions like lactulose and rifaximin. Ethical approval was not required as the study is based on existing data.

Results

From the literature search, a total of 35 relevant studies were included in the analysis. These studies focused on the diagnostic and therapeutic approaches for hepatic encephalopathy (HE), examining pathophysiological mechanisms, psychometric assessment tools, and treatment strategies. The following key findings were identified:

1. **Pathophysiology of HE:**

The most common pathophysiological mechanisms involved in HE include ammonia toxicity, oxidative stress, and neuroinflammation. Studies showed that the accumulation of ammonia in the bloodstream, primarily produced by gut bacteria during the digestion of proteins, leads to cerebral edema and altered neurotransmission. The gut-liver-brain axis was emphasized as a crucial pathway in HE development, with intestinal dysbiosis playing a significant role in exacerbating symptoms.

2. **Psychometric Hepatic Encephalopathy Score (PHES):**

Among the diagnostic tools, the PHES was highlighted as an essential instrument for assessing cognitive dysfunction in HE patients. The review indicated that PHES, which includes tasks such as digit symbol substitution and serial dotting test, has a strong correlation with clinical assessment of HE, especially in its early stages, where symptoms are minimal but neurocognitive impairments are detectable.

3. **Therapeutic Approaches:**

1. Lactulose remains the first-line treatment for HE. It works by reducing ammonia production in the gut and enhancing its excretion. Many studies showed that lactulose, often combined with rifaximin, significantly improves cognitive function and reduces hospital readmission rates in HE patients.
2. Rifaximin, a non-absorbable antibiotic, was noted as an effective adjunct to lactulose. It reduces the gut bacterial load, specifically targeting ammonia-producing bacteria. Clinical trials highlighted that rifaximin not only improved mental status but also reduced the risk of HE recurrence.
3. Other therapeutic modalities, such as the use of branched-chain amino acids (BCAAs), antibiotics like neomycin, and liver transplantation in end-stage cirrhosis cases, were reviewed but were found to have more variable outcomes. While BCAAs showed promise in improving cognitive function in certain studies, their use as a standard treatment was not fully supported.

4. Studies also discussed the significant impact of HE on patients' quality of life, with cognitive impairments leading to decreased daily functioning and psychological distress. PHES testing provided valuable insights into these impairments, enabling early interventions that could potentially prevent further progression to severe stages.

Discussion

The findings from this review reinforce the complexity of diagnosing and managing hepatic encephalopathy. The current first-line treatment approach, combining lactulose with rifaximin, remains effective, with significant improvements in cognitive function and a reduction in HE recurrence. However, the role of newer therapies, such as probiotics and BCAAs, requires further investigation. Although promising, these treatments should be tested in larger, well-designed randomized controlled trials to determine their efficacy and safety compared to traditional therapies.

The importance of early diagnosis using PHES was evident. Given that HE can be subtle in its early stages, the use of psychometric tools is essential for identifying minimal HE (MHE) before clinical symptoms appear. Early intervention may prevent the progression to more severe forms of encephalopathy and ultimately improve patient outcomes.

Moreover, the gut-liver-brain axis continues to emerge as a critical target for HE management. Interventions aimed at restoring gut microbiota balance could potentially become an important adjunct in treatment. The growing body of evidence supports the idea that a multifaceted approach, including gut microbiome modulation, ammonia reduction, and cognitive support, is necessary for effective HE management.

Despite the therapeutic advances, challenges remain in managing advanced stages of HE, especially in patients with end-stage liver disease. In these cases, liver transplantation offers the only definitive treatment option, though not without its own risks and complications.

In conclusion, while current treatments for hepatic encephalopathy, particularly lactulose and rifaximin, provide significant improvements, further research into alternative therapies, early diagnostic tools, and the role of the gut microbiome is needed to enhance treatment outcomes and quality of life for patients with HE.

CONCLUSION: Treatment of hepatic encephalopathy is based on protein restriction in the diet, 'sterilisation' of the bowel with antibacterial drugs and administration of lactulose, administration of branched-chain amino acids. Surgical removal of the porto-tocaval shunt may result in regression of the portosystemic encephalopathy that developed after the shunt was implanted. In some cases, removal of the artificial shunt can be achieved by endovascular methods using a balloon [Potts J. et al., 1990] or spiral [Clarke B. et al., 1989]. Embolization is also used to close spontaneous splenorenal anastomoses [Kawanaka H. et al., 1995].

References:

1. Толибов, Ф. (2024). ИММУННАЯ СИСТЕМА: АНАТОМИЯ ЛИМФАТИЧЕСКОЙ СИСТЕМЫ И МЕХАНИЗМЫ ИММУННОГО ОТВЕТА. Журнал академических исследований нового Узбекистана, 1(2), 55-58.
2. Farxodivich, T. F. (2024). The Syndrome of External Secretory Function Insufficiency is a Common Complication of Chronic Pancreatitis.American Journal of Bioscience and Clinical Integrity 1 (10), 90-95
3. Farxodivich, T. F. (2024). Clinical Characteristics of Gastritis in Digestive Diseases. Research Journal of Trauma and Disability Studies, 3(3), 294-299.
4. Farxodivich, T. F. (2024). INFECTION OF COVID-19 ON COGNITIVE FUNCTIONS. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(4), 325-330.
5. *Tolibov F.F.* - VIOLATION OF PLATELET AGGREGATION AND IMBALANCE OF HEMOSTASIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C//New Day in Medicine 6(68)2024 264-268 https://newdayworldmedicine.com/en/article/3758
6. *Tolibov F.F.*- CLINICAL AND MORPHOLOGICAL CORRELATIONS OF LIVER CIRRHOSIS.European Journal of Modern Medicine and Practice 4 (11), 515-520
7. Zikrillaev, F. A. (2024). Cardiorehabilitations from Physiotherapeutic Treatments in Cardiovascular Diseases. *American Journal of Bioscience and Clinical Integrity*, *1*(10), 96-102.
8. Зикриллаев, Ф. А. (2024). ОПРЕДЕЛЕНИЕ РАННИХ ФАКТОРОВ РИСКА ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК В ПУБЕРТНОМ ВОЗРАСТЕ. *Modern education and development*, *16*(7), 166-180.
9. Зикриллаев, Ф. А. (2024). РОЛЬ ПРЕПАРАТОВ ЛЕРКАНИДИПИНА И АМЛОДИПИНА В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. *Modern education and development*, *16*(7), 213-229.
10. Abdurashitovich, Z. F. (2024). DETERMINATION OF THE ETIOPATHOGENESIS AND RISK FACTORS OF OBESITY AMONG ADOLESCENTS. *Modern education and development*, *16*(7), 181-194.
11. Abdurashitovich, Z. F. (2024). EARLY RISK FACTORS FOR ARTERIAL HYPERTENSION AND FEATURES OF ITS ASSOCIATION WITH OTHER DISEASES. *Modern education and development*, *16*(7), 195-212.
12. Abdurashitovich Z. F. ODAM ANATOMIYASI FANIDAN KALLA SUYAKLARI TUZILISHI VA SHAKLLANISHI HAQIDA //Modern education and development. – 2024. – Т. 16. – №. 7. – С. 149-165.
13. Zikrillaev, F. A. (2024). Metabolic Syndrome Calling Models. *American Journal of Bioscience and Clinical Integrity*, *1*(11), 66-71.
14. Abdurashitovich, Z. F. (2024). MUSHAKLAR TO'GRISIDA MA'LUMOT. MUSHAKLARNING TARAQQIYOTI. MUSHAKLARNING YORDAMCHI APPARATI. *TADQIQOTLAR. UZ*, *40*(3), 94-100.
15. Abdurashitovich, Z. F. (2024). APPLICATION OF MYOCARDIAL CYTOPROTECTORS IN ISCHEMIC HEART DISEASES. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *39*(5), 152-159.
16. Abdurashitovich, Z. F. (2024). SIGNIFICANCE OF BIOMARKERS IN METABOLIC SYNDROME. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *4*(9), 409-413.

17. Zikrillaev, F. A. (2024). Cardiorehabilitations from Physiotherapeutic Treatments in Cardiovascular Diseases. *American Journal of Bioscience and Clinical Integrity*, *1*(10), 96-102.

18. Abdurashitovich, Z. F. (2024). Cardiovascular System. Heart. Aorta. Carotid Artery.

19. Abdurashitovich, Z. F. (2024). MORPHO-FUNCTIONAL ASPECTS OF THE DEEP VEINS OF THE HUMAN BRAIN. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *36*(6), 203-206.

20. Abdurashitovich, Z. F. (2024). ASTRAGAL O'SIMLIGINING TIBBIYOTDAGI MUHIM AHAMIYATLARI VA SOG'LOM TURMUSH TARZIGA TA'SIRI. *Лучшие интеллектуальные исследования*, *14*(4), 111-119.

21. Abdurashitovich, Z. F. (2024). ODAM ANATOMIYASI FANIDAN SINDESMOLOGIYA BO'LIMI HAQIDA UMUMIY MALUMOTLAR. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *41*(4), 37-45.

22. Abdurashitovich, Z. F. (2024). THE IMPORTANCE OF THE ASTRAGAL PLANT IN MEDICINE AND ITS EFFECT ON A HEALTHY LIFESTYLE. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *41*(4), 88-95.

23. Abdurashitovich, Z. F. (2024). Department of Syndesmology from the Science of Human Anatomy General Information About. *Research Journal of Trauma and Disability Studies*, *3*(3), 158-165.

24. Abdurashitovich, Z. F. (2024). THE COMPLEXITY OF THE FUSION OF THE BONES OF THE FOOT. *JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH*, *3*(5), 223-230.

25. Abdurashitovich, Z. F. (2024). ANATOMICAL COMPLEXITIES OF JOINT BONES OF THE HAND. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *4*(4), 198-206.

26. Зикриллаев, Ф. А. (2024). АНАТОМИЧЕСКОЕ СТРОЕНИЕ ОРГАНОВ ДЫХАНИЯ И ЕГО ЛИЧНЫЕ ХАРАКТЕРИСТИКИ. *TADQIQOTLAR. UZ*, *40*(3), 86-93.

27. Abdurashitovich, Z. F., & Komoliddinovich, S. J. (2024). DIGESTIVE SYSTEM. ANATOMY OF THE STOMACH. *TADQIQOTLAR. UZ*, *40*(3), 78-85.

28. Abdurashitovich, Z. F. (2024). UMURTQA POG'ONASI BIRLASHUVLARI. *TADQIQOTLAR. UZ*, *40*(3), 40-47.

29. Rakhmatova, D. B., & Zikrillaev, F. A. (2022). DETERMINE THE VALUE OF RISK FACTORS

30. Toxirovna, E. G. (2024). QALQONSIMON BEZ KASALLIKLARIDAN HASHIMOTO TIREODIT KASALLIGINING MORFOFUNKSIONAL O'ZIGA XOSLIGI. *Modern education and development*, *16*(7), 120-135.

31. Toxirovna, E. G. (2024). REVMATOID ARTRIT: BO'G'IMLAR YALLIG'LANISHINING SABABLARI, KLINIK BELGILARI, OQIBATLARI VA ZAMONAVIY DAVOLASH YONDASHUVLARI. *Modern education and development*, *16*(7), 136-148.

32. Эргашева, Г. Т. (2024). ОЦЕНКА КЛИНИЧЕСКОЙ ЭФФЕКТИВНОСТИ ОРЛИСТАТА У БОЛЬНЫХ ОЖИРЕНИЕМ И АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ. *Modern education and development*, *16*(7), 92-105.

33. Ergasheva, G. T. (2024). THE SPECIFICITY OFAUTOIMMUNE THYROIDITIS IN PREGNANCY. *European Journal of Modern Medicine and Practice*, *4*(11), 448-453.

34. Эргашева, Г. Т. (2024). ИССЛЕДОВАНИЕ ФУНКЦИИ ЩИТОВИДНОЙ ЖЕЛЕЗЫ ПРИ ТИРЕОИДИТЕ ХАШИМОТО. *Modern education and development*, *16*(7), 106-119.

35. Toxirovna, E. G. (2024). GIPOFIZ ADENOMASINI NAZORAT QILISHDA KONSERVATIV JARROHLIK VA RADIATSIYA TERAPIYASINING UZOQ MUDDATLI SAMARADORLIGI. *Modern education and development*, *16*(7), 79-91.

36. ERGASHEVA, G. T. (2024). OBESITY AND OVARIAN INSUFFICIENCY. *Valeology: International Journal of Medical Anthropology and Bioethics*, *2*(09), 106-111.

37. Ergasheva, G. T. (2024). Modern Methods in the Diagnosis of Autoimmune Thyroiditis. *American Journal of Bioscience and Clinical Integrity*, *1*(10), 43-50.

38. Tokhirovna, E. G. (2024). COEXISTENCE OF CARDIOVASCULAR DISEASES IN PATIENTS WITH TYPE 2 DIABETES. *TADQIQOTLAR. UZ*, *40*(3), 55-62.

39. Toxirovna, E. G. (2024). DETERMINATION AND STUDY OF GLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH COMORBID DISEASES. *TADQIQOTLAR. UZ*, *40*(3), 71-77.

40. Erkinjonovna, S. N. (2024). ARTERIAL HYPERTENSION IN PATIENTS WITH GOUT AND SYMPTOMATIC HYPERURICEMIA. *Modern education and development*, *16*(9), 293-305.

41. Sharapova, N. E. (2024). MODERN DIAGNOSTICS OF RESISTANT ARTERIAL HYPERTENSION. *EUROPEAN JOURNAL OFMODERNMEDICINEAND PRACTICE*, *4*(11), 436-442.

42. Toxirovna, E. G. (2024). XOMILADORLIKDA QANDLI DIABET KELTIRIB CHIQARUVCHI XAVF OMILLARINI ERTA ANIQLASH USULLARI. *TADQIQOTLAR. UZ*, *40*(3), 63-70.

43. Toxirovna, E. G. (2024). QANDLI DIABET 2-TIP VA KOMORBID KASALLIKLARI BO'LGAN BEMORLARDA GLIKEMIK NAZORAT. *TADQIQOTLAR. UZ*, *40*(3), 48-54.

44. Tokhirovna, E. G. (2024). MECHANISM OF ACTION OF METFORMIN (BIGUANIDE) IN TYPE 2 DIABETES. *JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH*, *3*(5), 210-216.

45. Tokhirovna, E. G. (2024). THE ROLE OF METFORMIN (GLIFORMIN) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. *EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE*, *4*(4), 171-177.

46. Эргашева, Г. Т. (2024). Эффект Применения Бигуанида При Сахарным Диабетом 2 Типа И Covid-19. *Research Journal of Trauma and Disability Studies*, *3*(3), 55-61.

47. Toxirovna, E. G. (2024). QANDLI DIABET 2 TUR VA YURAK QON TOMIR KASALLIKLARINING BEMOLARDA BIRGALIKDA KECHISHI. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *38*(7), 202-209.

48. Эргашева, Г. Т. (2024). СОСУЩЕСТВОВАНИЕ ДИАБЕТА 2 ТИПА И СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У ПАЦИЕНТОВ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *38*(7), 219-226.

49. Эргашева, Г. Т. (2024). СНИЖЕНИЕ РИСКА ОСЛОЖНЕНИЙ У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2 ТИПА И СЕРДЕЧНО-СОСУДИСТЫМИ ЗАБОЛЕВАНИЯМИ. *Образование Наука И Инновационные Идеи В Мире*, *38*(7), 210-218.

50. Tokhirovna, E. G. (2024). CLINICAL AND MORPHOLOGICAL ASPECTS OF THE COURSE OF ARTERIAL HYPERTENSION. *Лучшие интеллектуальные исследования*, *12*(4), 234-243.

51. Tokhirovna, E. G. Studying the Causes of the Relationship between Type 2 Diabetes and Obesity. *Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN*, 2456-6470.

52. Toxirovna, E. G. (2024). ARTERIAL GIPERTENZIYA KURSINING KLINIK VA MORFOLOGIK JIHATLARI. *Лучшие интеллектуальные исследования*, *12*(4), 244-253.

53. Эргашева, Г. Т. (2023). Исследование Причин Связи Диабета 2 Типа И Ожирения. *Research Journal of Trauma and Disability Studies*, *2*(12), 305-311.